Please login to the form below

Not currently logged in


This page shows the latest Praluent news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

Earlier this month Sanofi and Regeneron announced a massive price cut to their cholesterol treatment Praluent in the US in order to perk up disappointing sales – and now rivals Amgen has ... to Praluent's US price, down from $14, 600 to between $4, 500

Latest news

More from news
Approximately 21 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    Repatha from Amgen was the first in the class to be approved in Japan in January, although it will likely only be months before Sanofi's rival Praluent will join it

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... We are very much encouraging collaboration, so we are

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

GDPR and events. What does the pharma industry need to know?
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...